Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

18.6%

583 terminated/withdrawn out of 3131 trials

Success Rate

78.1%

-8.4% vs industry average

Late-Stage Pipeline

36%

1138 trials in Phase 3/4

Results Transparency

67%

1394 of 2077 completed trials have results

Key Signals

209 recruiting1394 with results463 terminated120 withdrawn

Enrollment Performance

Analytics

Phase 2
899(33.2%)
Phase 3
743(27.4%)
Phase 1
621(22.9%)
Phase 4
395(14.6%)
N/A
46(1.7%)
Early Phase 1
7(0.3%)
2711Total
Phase 2(899)
Phase 3(743)
Phase 1(621)
Phase 4(395)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3131)

Showing 20 of 3131 trials
NCT05432388Phase 2Completed

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Role: lead

NCT07644364Phase 1Not Yet Recruiting

HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension

Role: lead

NCT03570892Phase 3Completed

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Role: lead

NCT07644351Completed

A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

Role: lead

NCT07549516Recruiting

A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

Role: lead

NCT05161195Phase 4Active Not Recruiting

Roll-over Study to Allow Continued Access to Ribociclib

Role: lead

NCT05038735Phase 3Active Not Recruiting

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Role: lead

NCT05252585Phase 4Active Not Recruiting

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Role: lead

NCT07340138Phase 1Recruiting

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Role: lead

NCT03040973Phase 2Active Not Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Role: lead

NCT06401356Phase 3Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Role: lead

NCT07357727Phase 3Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Role: lead

NCT06875973Phase 3Recruiting

Pelacarsen Roll-over Extension Program

Role: lead

NCT01872260Phase 1Active Not Recruiting

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Role: lead

NCT04524000Phase 2Active Not Recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Role: lead

NCT06997588Phase 2Recruiting

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Role: lead

NCT07378969Recruiting

A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy

Role: lead

NCT04094311Phase 3Recruiting

Study of Out of Specification for Tisagenlecleucel

Role: lead

NCT05548062Active Not Recruiting

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

Role: lead

NCT06665256Phase 2Active Not Recruiting

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Role: lead